Financial relationships between board‐certified neurologists and the pharmaceutical industry in Japan

Murayama, Anju; Higuchi, Kenichi; Senoo, Yuki

doi:10.1002/ctd2.268

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 24 , 33 The database included information on speaking fees, consultancy payments, and writing compensation, which pharmaceutical companies provided to individual health care providers from 2016 to 2020, aligning with the data collection methods of prior studies. 28 , 34 , 35 All pharmaceutical firms and their subsidiaries affiliated with the Japan Pharmaceutical Manufacturers Association (JPMA), the foremost trade organization in Japan's pharmaceutical sector, were mandated to disclose payments to individual health care providers with the providers' names. 36 These payments are for activities such as delivering lectures at industry‐sponsored events, offering consultancy services, and creating manuscripts and pamphlets.…”

Section: Methodsmentioning

confidence: 99%

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Murayama,

Aizawa,

Byreddy

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

Background Clinical practice guidelines (CPGs) offer disease management recommendations based on scientific evidence. However, financial conflicts of interest between CPG developers and the pharmaceutical industry could bias these recommendations, potentially affecting patient care. Proper management of these conflicts of interest is particularly crucial for maintaining the integrity of CPGs. The study aimed to evaluate the extent of financial relationships between the pharmaceutical industry and authors of CPGs for cardiovascular diseases in Japan. Methods and Results The study analyzed personal payments from the pharmaceutical industry to authors of cardiovascular disease CPGs published by the Japanese Circulation Society from January 2015 to December 2022. Payment data, including speaking, consultancy, and writing fees from 2016 to 2020, were extracted from a publicly available database containing personal payments disclosed by all major pharmaceutical companies. A total of 929 unique authors from 37 eligible Japanese Circulation Society CPGs were identified. Notably, 94.4% of these authors received personal payments from pharmaceutical companies, totaling >US $70.8 million. The mean±SD payment per author was US $76 314±138 663) and the median payment per author was US $20 792 (interquartile range: US $4262–US $76 998) over the 5‐year period. Chairs of CPGs received significantly higher payments than other authors. More than 80% of authors in each CPG received personal payments. Conclusions The study elucidated that there were considerable financial relationships between pharmaceutical companies and cardiology CPG authors in Japan. This finding deviates from international conflict of interest management policies, suggesting the need for more stringent conflict of interest management strategies by the Japanese Circulation Society to ensure the development of trustworthy and evidence‐based CPGs.

show abstract

Section: Methodsmentioning

confidence: 99%

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Murayama,

Aizawa,

Byreddy

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous research using this database revealed prevalent financial relationships between physicians and pharmaceutical companies in Japan. 19 30 …”

Section: Introductionmentioning

confidence: 99%

Non-research payments to board-certified cardiologists from pharmaceutical industry in Japan from 2016 to 2019: a retrospective analysis

Murayama,

Higuchi,

Senoo

2024

BMJ Open

Self Cite

View full text Add to dashboard Cite

ObjectivesTo evaluate the extent and trends of personal payments from pharmaceutical companies to cardiologists board-certified by the Japanese Circulation Society.DesignA retrospective analysis study using data from a publicly available database.SettingThe study focused on payments to cardiologists in Japan.ParticipantsAll 15 048 cardiologists who were board-certified by the Japanese Circulation Society as of 2021.Primary and secondary outcome measuresThe primary outcome was the extent of personal payments to cardiologists in 2016–19. Secondary outcomes included the analysis of trends in these payments over the same period.ResultsOf all 15 048 board-certified cardiologists, 9858 (65.5%) received personal payments totaling $112 934 503 entailing 165 013 transactions in 2016–19. The median payment per cardiologist was $2947 (IQR, $1022–$8787), with a mean of $11 456 (SD, $35 876). The Gini Index was 0.840, indicating a high concentration of payments to a small number of cardiologists. The top 1%, 5% and 10% of cardiologists received 31.6%, 59.4% and 73.5% of all payments, respectively. There were no significant trends in the number of cardiologists receiving payments or number of payments per cardiologist during the study period.ConclusionsMore than 65% of Japanese cardiologists received personal payments from pharmaceutical companies over the 4-year study period. Although the payment amount was relatively small for the majority of cardiologists, a small number of cardiologists received the vast majority of the payments.

show abstract

Cross‐sectional analysis of pharmaceutical industry payments to board‐certified breast cancer specialists in Japan

Murayama,

Higuchi,

Kugo

2024

Clinical and Translational Dis

View full text Add to dashboard Cite

Financial interactions between pharmaceutical companies and physicians introduce conflicts of interest among physicians, and can unduly influence physicians' clinical decision‐making, such as increased use of non‐recommended cancer treatments and higher healthcare expenditures. Breast cancer is the most common cancer for which there is a growing number of novel treatments. Nevertheless, the financial relationships between pharmaceutical companies and physicians treating patients with breast cancer remain unknown. Using payment data disclosed by major pharmaceutical companies in Japan between 2016 and 2020, this study examined size and trends in non‐research payments from the pharmaceutical companies to breast cancer specialists who were board‐certified by the Japanese Breast Cancer Society. A total of $17.2 million were made to 1349 or 77.8% of all board‐certified breast cancer specialists over the five years. Of all specialists, 41.9% to 55.5% received the payments each year. The median payments per specialist were $1,149–$1,371 annually. Only 5op 1% and 10% of all specialists received 24.7% and 70.3% of all payments to the specialists. The payments per specialist significantly increased by 9.9% (95% confidence interval: 6.713.1, p < 0.001) from 2016 to 2019, but decreased by 29.6% (95% CI: −34.4 to −24.5, p < 0.001) in 2020 when the COVID‐19 pandemic occurred. Given that even a small payment to physicians is associated with their clinical practice, it is imperative that these breast cancer specialists are more aware of the potential influence of payments on their decision‐making.

show abstract

Financial relationships between board‐certified neurologists and the pharmaceutical industry in Japan

Cited by 3 publications

References 29 publications

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Non-research payments to board-certified cardiologists from pharmaceutical industry in Japan from 2016 to 2019: a retrospective analysis

Cross‐sectional analysis of pharmaceutical industry payments to board‐certified breast cancer specialists in Japan

Contact Info

Product

Resources

About